JP2018520161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520161A5 JP2018520161A5 JP2018500585A JP2018500585A JP2018520161A5 JP 2018520161 A5 JP2018520161 A5 JP 2018520161A5 JP 2018500585 A JP2018500585 A JP 2018500585A JP 2018500585 A JP2018500585 A JP 2018500585A JP 2018520161 A5 JP2018520161 A5 JP 2018520161A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 86
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 73
- 125000001072 heteroaryl group Chemical group 0.000 claims 72
- 125000003118 aryl group Chemical group 0.000 claims 65
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 62
- 150000001875 compounds Chemical class 0.000 claims 52
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 claims 47
- 150000003839 salts Chemical class 0.000 claims 34
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 30
- 125000001475 halogen functional group Chemical group 0.000 claims 30
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000001188 haloalkyl group Chemical group 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 17
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 9
- 206010009887 colitis Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- -1 —N 3 Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000000464 thioxo group Chemical group S=* 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010056979 Colitis microscopic Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000000616 Hemoptysis Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 208000004044 Hypesthesia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010023232 Joint swelling Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010024648 Livedo reticularis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000008771 Lymphadenopathy Diseases 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000037039 Monarthritis Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010031009 Oral pain Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010034719 Personality change Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 claims 1
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000008240 chemical colitis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000019902 chronic diarrheal disease Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 208000034783 hypoesthesia Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 201000008254 ileocolitis Diseases 0.000 claims 1
- 208000027138 indeterminate colitis Diseases 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 208000004341 lymphocytic colitis Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000008275 microscopic colitis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000035824 paresthesia Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- QJOXCEGGCSBIIE-VWLOTQADSA-N CC(C)(C)CNc(c(cc(C[C@H](C1=CN(C2CC2)NN1)c1cccc2c1ccnc2)cc1Cl)c1nc1)c1C#N Chemical compound CC(C)(C)CNc(c(cc(C[C@H](C1=CN(C2CC2)NN1)c1cccc2c1ccnc2)cc1Cl)c1nc1)c1C#N QJOXCEGGCSBIIE-VWLOTQADSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189158P | 2015-07-06 | 2015-07-06 | |
| US62/189,158 | 2015-07-06 | ||
| US201562269060P | 2015-12-17 | 2015-12-17 | |
| US62/269,060 | 2015-12-17 | ||
| PCT/US2016/040520 WO2017007689A1 (en) | 2015-07-06 | 2016-06-30 | Cot modulators and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018171794A Division JP6781221B2 (ja) | 2015-07-06 | 2018-09-13 | Ｃｏｔモジュレーターおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520161A JP2018520161A (ja) | 2018-07-26 |
| JP2018520161A5 true JP2018520161A5 (OSRAM) | 2018-09-06 |
| JP6430060B2 JP6430060B2 (ja) | 2018-11-28 |
Family
ID=56411943
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500585A Active JP6430060B2 (ja) | 2015-07-06 | 2016-06-30 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2018171794A Active JP6781221B2 (ja) | 2015-07-06 | 2018-09-13 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2019137759A Active JP6906021B2 (ja) | 2015-07-06 | 2019-07-26 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2020208330A Active JP7138155B2 (ja) | 2015-07-06 | 2020-12-16 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2022065168A Withdrawn JP2022082816A (ja) | 2015-07-06 | 2022-04-11 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2024081151A Withdrawn JP2024100865A (ja) | 2015-07-06 | 2024-05-17 | Ｃｏｔモジュレーターおよびその使用方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018171794A Active JP6781221B2 (ja) | 2015-07-06 | 2018-09-13 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2019137759A Active JP6906021B2 (ja) | 2015-07-06 | 2019-07-26 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2020208330A Active JP7138155B2 (ja) | 2015-07-06 | 2020-12-16 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2022065168A Withdrawn JP2022082816A (ja) | 2015-07-06 | 2022-04-11 | Ｃｏｔモジュレーターおよびその使用方法 |
| JP2024081151A Withdrawn JP2024100865A (ja) | 2015-07-06 | 2024-05-17 | Ｃｏｔモジュレーターおよびその使用方法 |
Country Status (41)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2729448E (pt) | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| ES2849953T3 (es) | 2015-07-06 | 2021-08-24 | Gilead Sciences Inc | 6-amino-quinolina-3-carbonitrilos como moduladores de cot |
| CN109879859B (zh) * | 2015-07-06 | 2022-01-25 | 吉利德科学公司 | Cot调节剂及其使用方法 |
| CA3029457A1 (en) | 2016-06-30 | 2018-01-04 | Gilead Sciences, Inc. | 4,6-diaminoquinazolines as cot modulators and methods of use thereof |
| JP6716785B2 (ja) * | 2016-08-19 | 2020-07-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| EA036921B1 (ru) * | 2017-02-10 | 2021-01-15 | Джилид Сайэнс, Инк. | Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич |
| CN108794516A (zh) * | 2017-04-26 | 2018-11-13 | 上海时莱生物技术有限公司 | 硼酸和硼酸酯类化合物及其制备方法和用途 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| WO2019065516A1 (ja) * | 2017-09-26 | 2019-04-04 | 日本曹達株式会社 | キノリン化合物および農園芸用殺菌剤 |
| ES2958828T3 (es) | 2018-02-15 | 2024-02-15 | Gilead Sciences Inc | Derivados de piridina y su uso para tratar una infección por VIH |
| PL3752496T3 (pl) | 2018-02-16 | 2023-11-27 | Gilead Sciences, Inc. | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| CN110294660B (zh) * | 2018-03-23 | 2021-09-24 | 中国农业大学 | 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法 |
| CN108658996A (zh) * | 2018-06-25 | 2018-10-16 | 中国药科大学 | 一种氘代Fiduxosin的制备方法 |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| TWI770527B (zh) * | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| JP7612663B2 (ja) | 2019-08-09 | 2025-01-14 | イドルシア・ファーマシューティカルズ・リミテッド | （２－アセタミジル）チオ－ベータ－ｄ－ガラクトピラノシド誘導体 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| ES3015725T3 (en) | 2019-08-15 | 2025-05-07 | Idorsia Pharmaceuticals Ltd | 2-hydroxycycloalkane-1-carbamoyl derivatives |
| AU2020338816A1 (en) | 2019-08-29 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Alpha-D-galactopyranoside derivatives |
| AU2020391466B2 (en) | 2019-11-26 | 2024-05-23 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| EP4126231A1 (en) * | 2020-03-30 | 2023-02-08 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| CN115397824B (zh) | 2020-04-02 | 2024-10-22 | 吉利德科学公司 | 用于制备cot抑制剂化合物的方法 |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| EP4225752B1 (en) | 2020-10-06 | 2024-12-11 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| IL304923A (en) | 2021-02-09 | 2023-10-01 | Idorsia Pharmaceuticals Ltd | History of hydroxyheterocycloalkane-carbamoyl |
| ES3033422T3 (en) | 2021-03-03 | 2025-08-04 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
| TW202345826A (zh) | 2021-06-04 | 2023-12-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
| EP4352058A4 (en) * | 2021-06-11 | 2025-09-24 | Neuronascent Inc | METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF SMALL MOLECULE THERAPIES WITH LIPOPHILIC HETEROCYCLIC TYPES |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| WO2024245157A1 (zh) * | 2023-05-30 | 2024-12-05 | 浙江星浩澎博医药有限公司 | 氮杂喹啉环衍生物 |
| WO2024249983A1 (en) * | 2023-06-02 | 2024-12-05 | Westol, Llc | 2,8-dihydroxyquinoline glucuronide derivatives with enhanced properties for use as anticancer, antiviral, antimicrobial, and other therapeutic applications |
| WO2025020886A1 (zh) * | 2023-07-27 | 2025-01-30 | 浙江星浩澎博医药有限公司 | 氮杂喹唑啉环衍生物及其用途 |
| KR102732584B1 (ko) | 2024-03-28 | 2024-11-21 | (주)신한티이씨 | 전기 배전반의 화재 위험 감지 및 진압용 소화 장치 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3930837A (en) | 1971-12-31 | 1976-01-06 | Ici Australia Limited | 3-chloro-5-acetamidaisoquinoline as a herbicide |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4151298A (en) | 1977-01-10 | 1979-04-24 | Ciba-Geigy Corporation | Anthelmintic compositions |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP2634438B2 (ja) | 1988-07-26 | 1997-07-23 | 三井東圧化学株式会社 | 不斉ビスオキサゾリルピリジン誘導体およびその製造方法 |
| DE4014171A1 (de) | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
| GB9310700D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Novel composition |
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| WO1999011124A1 (fr) | 1997-08-28 | 1999-03-11 | Nissan Chemical Industries, Ltd. | Agents antibacteriens et antifongiques, algicides et agents antisalissure a base de cyanoacrylate, a usage industriel |
| CA2336691C (en) | 1998-07-10 | 2009-02-10 | Massachusetts Institute Of Technology | Ligands for metals and metal-catalyzed processes |
| HU230728B1 (hu) * | 1998-09-29 | 2017-12-28 | Wyeth Holdings Llc | Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai |
| NZ535365A (en) | 2002-03-20 | 2006-07-28 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| KR100751604B1 (ko) | 2003-03-03 | 2007-08-22 | 에프. 호프만-라 로슈 아게 | 5-ｈｔ6 조절자로서 사용되는 2,5- 및 2,6-치환된테트라하이드로아이소퀴놀린 |
| MXPA06001590A (es) | 2003-08-19 | 2006-05-19 | Wyeth Corp | Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos. |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| TW200529846A (en) * | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| BRPI0611521A2 (pt) * | 2005-05-18 | 2010-09-14 | Wyeth Corp | inibidores de 4,6-diamino-[1,7]naftiridina-3-carbonitrila de quìnase tpl2 e métodos de fabricação e uso dos mesmos |
| EP1888529A2 (en) * | 2005-05-18 | 2008-02-20 | Wyeth | 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same |
| CN102516176A (zh) | 2005-10-28 | 2012-06-27 | 雅培制药有限公司 | 抑制trpv1受体的吲唑衍生物 |
| EP2001480A4 (en) | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
| US7741354B2 (en) | 2006-11-09 | 2010-06-22 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| CN101583601B (zh) | 2007-01-17 | 2013-06-05 | 香港科技大学 | 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物 |
| GB0820856D0 (en) | 2008-11-14 | 2008-12-24 | Univ Leuven Kath | Novel inhibitors of flavivirus replication |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| GB0922302D0 (en) | 2009-12-22 | 2010-02-03 | Imp Innovations Ltd | Compounds |
| AU2011224410B2 (en) | 2010-03-09 | 2015-05-28 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| JP5730389B2 (ja) | 2010-06-09 | 2015-06-10 | 天津和美生物技術有限公司 | シアノキノリン誘導体 |
| EP2708540B1 (en) | 2011-05-10 | 2018-07-25 | Kyowa Hakko Kirin Co., Ltd. | Pyrimido-diazepinone compound |
| WO2013004652A1 (de) | 2011-07-04 | 2013-01-10 | Bayer Intellectual Property Gmbh | Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| KR101998442B1 (ko) | 2011-10-27 | 2019-07-09 | 다이쇼 세이야꾸 가부시끼가이샤 | 아졸 유도체 |
| DK2776038T3 (en) | 2011-11-11 | 2018-04-23 | Gilead Apollo Llc | ACC INHIBITORS AND APPLICATIONS THEREOF |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| CN103483363B (zh) | 2012-06-13 | 2016-12-21 | 上海赛迦化工产品有限公司 | 多样性的手性氨基硼酸及其制备方法和应用 |
| IN2015DN03795A (OSRAM) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
| CN103408572B (zh) | 2013-07-12 | 2015-12-02 | 上海工程技术大学 | 手性氨基硼酸衍生物及其制备方法和应用 |
| KR102380609B1 (ko) | 2013-12-12 | 2022-03-30 | 리커리엄 아이피 홀딩스, 엘엘씨 | 바이사이클릭 알킬 화합물 및 합성 |
| US10654812B2 (en) | 2014-03-07 | 2020-05-19 | Recurium Ip Holdings Llc | Propellane derivates and synthesis |
| EP3166938A4 (en) * | 2014-07-11 | 2018-01-17 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
| KR20170048588A (ko) | 2014-09-17 | 2017-05-08 | 카리라 파마슈티컬스, 아이앤씨. | 바이사이클릭 화합물 |
| MX2017003933A (es) | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| PT3237404T (pt) | 2014-12-23 | 2021-01-19 | Gilead Sciences Inc | Processos de preparação de inibidores ask1 |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| BR112017014341A2 (pt) | 2015-01-09 | 2018-03-27 | Gilead Apollo, Llc | método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição. |
| JP6580145B2 (ja) | 2015-01-16 | 2019-09-25 | スリーエム イノベイティブ プロパティズ カンパニー | グリッド出力を改善するグリッド行動を選択するためのシステム及び方法 |
| ES2849953T3 (es) * | 2015-07-06 | 2021-08-24 | Gilead Sciences Inc | 6-amino-quinolina-3-carbonitrilos como moduladores de cot |
| CN109879859B (zh) | 2015-07-06 | 2022-01-25 | 吉利德科学公司 | Cot调节剂及其使用方法 |
| ES2920888T3 (es) | 2015-12-31 | 2022-08-11 | Hitgen Inc | Derivado de sulfonamida y método de preparación y uso del mismo |
| CN112920200A (zh) | 2016-03-02 | 2021-06-08 | 吉利德阿波罗公司 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| WO2017221944A1 (ja) | 2016-06-21 | 2017-12-28 | パナソニックヘルスケアホールディングス株式会社 | カタラーゼ阻害剤及びカタラーゼ阻害剤を用いるアナライトの測定方法 |
| CA3029457A1 (en) | 2016-06-30 | 2018-01-04 | Gilead Sciences, Inc. | 4,6-diaminoquinazolines as cot modulators and methods of use thereof |
| CN106512014A (zh) | 2016-10-27 | 2017-03-22 | 武汉大学 | 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 |
| JP2020509047A (ja) | 2017-03-03 | 2020-03-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ａｃｃ阻害剤およびその固体形態を調製するためのプロセス |
| JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
| CA3059883A1 (en) | 2017-04-12 | 2018-10-18 | Gilead Sciences, Inc. | Methods of treating liver disease |
| JP7479278B2 (ja) | 2017-10-06 | 2024-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ａｃｃ阻害剤を含む併用療法 |
| EP3927683A1 (en) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| WO2020185685A1 (en) | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating acne |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| EP4126231A1 (en) | 2020-03-30 | 2023-02-08 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| CN115397824B (zh) | 2020-04-02 | 2024-10-22 | 吉利德科学公司 | 用于制备cot抑制剂化合物的方法 |
| TW202345826A (zh) | 2021-06-04 | 2023-12-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
-
2016
- 2016-06-30 CN CN201910292757.5A patent/CN109879859B/zh active Active
- 2016-06-30 PE PE2017002804A patent/PE20180462A1/es unknown
- 2016-06-30 SG SG11201702041PA patent/SG11201702041PA/en unknown
- 2016-06-30 AU AU2016290820A patent/AU2016290820B2/en active Active
- 2016-06-30 KR KR1020187003221A patent/KR101974793B1/ko active Active
- 2016-06-30 LT LTEP16738976.6T patent/LT3191470T/lt unknown
- 2016-06-30 ES ES21162393T patent/ES3034100T3/es active Active
- 2016-06-30 EP EP25176778.6A patent/EP4613332A3/en active Pending
- 2016-06-30 ES ES18186568T patent/ES2872076T3/es active Active
- 2016-06-30 RS RS20190498A patent/RS58639B1/sr unknown
- 2016-06-30 PT PT181865684T patent/PT3456717T/pt unknown
- 2016-06-30 PT PT211623939T patent/PT3896064T/pt unknown
- 2016-06-30 SI SI201631907T patent/SI3896064T1/sl unknown
- 2016-06-30 KR KR1020207002878A patent/KR102443575B1/ko active Active
- 2016-06-30 DK DK16738976.6T patent/DK3191470T3/en active
- 2016-06-30 CN CN202210008753.1A patent/CN114380799B/zh active Active
- 2016-06-30 PL PL18186568T patent/PL3456717T3/pl unknown
- 2016-06-30 IL IL293770A patent/IL293770B2/en unknown
- 2016-06-30 CN CN202411260421.8A patent/CN119143730A/zh active Pending
- 2016-06-30 KR KR1020227031078A patent/KR20220129667A/ko not_active Ceased
- 2016-06-30 CR CR20170599A patent/CR20170599A/es unknown
- 2016-06-30 EP EP18186568.4A patent/EP3456717B1/en active Active
- 2016-06-30 CU CUP2017000172A patent/CU20170172A7/xx unknown
- 2016-06-30 HU HUE16738976A patent/HUE043310T2/hu unknown
- 2016-06-30 WO PCT/US2016/040520 patent/WO2017007689A1/en not_active Ceased
- 2016-06-30 EA EA201792613A patent/EA036788B1/ru unknown
- 2016-06-30 NZ NZ750707A patent/NZ750707A/en unknown
- 2016-06-30 ME MEP-2019-117A patent/ME03425B/me unknown
- 2016-06-30 SI SI201631197T patent/SI3456717T1/sl unknown
- 2016-06-30 CA CA2971640A patent/CA2971640C/en active Active
- 2016-06-30 NZ NZ738525A patent/NZ738525A/en unknown
- 2016-06-30 SI SI201630202T patent/SI3191470T1/sl unknown
- 2016-06-30 KR KR1020197011792A patent/KR102073641B1/ko active Active
- 2016-06-30 PL PL21162393.9T patent/PL3896064T3/pl unknown
- 2016-06-30 KR KR1020247000058A patent/KR20240008398A/ko not_active Ceased
- 2016-06-30 IL IL274568A patent/IL274568B/en unknown
- 2016-06-30 MX MX2017004737A patent/MX370984B/es active IP Right Grant
- 2016-06-30 UA UAA201712984A patent/UA123010C2/uk unknown
- 2016-06-30 ES ES16738976T patent/ES2734713T3/es active Active
- 2016-06-30 PL PL16738976T patent/PL3191470T3/pl unknown
- 2016-06-30 MY MYPI2018700007A patent/MY196173A/en unknown
- 2016-06-30 HR HRP20190853TT patent/HRP20190853T1/hr unknown
- 2016-06-30 PT PT16738976T patent/PT3191470T/pt unknown
- 2016-06-30 EP EP21162393.9A patent/EP3896064B1/en active Active
- 2016-06-30 CN CN201680050602.5A patent/CN107922390B/zh active Active
- 2016-06-30 EP EP16738976.6A patent/EP3191470B1/en active Active
- 2016-06-30 JP JP2018500585A patent/JP6430060B2/ja active Active
- 2016-06-30 MA MA39422A patent/MA39422B1/fr unknown
- 2016-06-30 US US15/199,534 patent/US20170008905A1/en not_active Abandoned
- 2016-06-30 SM SM20190244T patent/SMT201900244T1/it unknown
- 2016-07-04 BR BR102016015656-4A patent/BR102016015656B1/pt active IP Right Grant
- 2016-07-05 TW TW107117905A patent/TWI699361B/zh active
- 2016-07-05 TW TW109122003A patent/TWI748539B/zh active
- 2016-07-05 TW TW105121281A patent/TWI634112B/zh active
- 2016-07-06 UY UY0001036771A patent/UY36771A/es not_active Application Discontinuation
-
2017
- 2017-02-09 US US15/429,086 patent/US9878995B2/en active Active
- 2017-04-18 SA SA517381350A patent/SA517381350B1/ar unknown
- 2017-12-20 IL IL256433A patent/IL256433B/en active IP Right Grant
- 2017-12-22 CL CL2017003356A patent/CL2017003356A1/es unknown
- 2017-12-22 CO CONC2017/0013351A patent/CO2017013351A2/es unknown
- 2017-12-22 EC ECIEPI201784635A patent/ECSP17084635A/es unknown
- 2017-12-22 SV SV2017005605A patent/SV2017005605A/es unknown
- 2017-12-26 DO DO2017000311A patent/DOP2017000311A/es unknown
-
2018
- 2018-01-03 PH PH12018500031A patent/PH12018500031A1/en unknown
- 2018-02-07 US US15/891,163 patent/US20180237455A1/en not_active Abandoned
- 2018-09-13 JP JP2018171794A patent/JP6781221B2/ja active Active
-
2019
- 2019-04-23 US US16/391,673 patent/US20190248807A1/en not_active Abandoned
- 2019-05-03 AU AU2019203122A patent/AU2019203122B2/en active Active
- 2019-05-20 CY CY20191100535T patent/CY1121750T1/el unknown
- 2019-05-29 IL IL266995A patent/IL266995B/en active IP Right Grant
- 2019-07-26 JP JP2019137759A patent/JP6906021B2/ja active Active
- 2019-12-17 US US16/717,074 patent/US11066414B2/en active Active
-
2020
- 2020-09-06 PH PH12020551397A patent/PH12020551397A1/en unknown
- 2020-10-20 AU AU2020257055A patent/AU2020257055B2/en active Active
- 2020-12-16 JP JP2020208330A patent/JP7138155B2/ja active Active
-
2021
- 2021-05-11 US US17/317,041 patent/US11905299B2/en active Active
-
2022
- 2022-04-11 JP JP2022065168A patent/JP2022082816A/ja not_active Withdrawn
- 2022-06-10 AU AU2022204050A patent/AU2022204050B2/en active Active
-
2023
- 2023-12-11 US US18/534,800 patent/US20240254137A1/en not_active Abandoned
-
2024
- 2024-05-17 JP JP2024081151A patent/JP2024100865A/ja not_active Withdrawn
- 2024-07-17 AU AU2024204902A patent/AU2024204902A1/en not_active Abandoned
-
2025
- 2025-04-14 US US19/177,702 patent/US20250346609A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520161A5 (OSRAM) | ||
| HRP20190853T1 (hr) | Cot modulatori i postupci za njihovu upotrebu | |
| AU2020205294B2 (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2013533884A5 (OSRAM) | ||
| EA023826B1 (ru) | Дигидропиримидинизохинолиноны и содержащие их фармацевтические композиции для лечения воспалительных нарушений | |
| JP2013530236A5 (OSRAM) | ||
| JP2013525433A5 (OSRAM) | ||
| JP2013525448A5 (OSRAM) | ||
| AU2019217320B2 (en) | Steroid derivative regulators, method for preparing the same, and uses thereof | |
| JP2013530238A5 (OSRAM) | ||
| JP2018511647A5 (OSRAM) | ||
| CA2797663A1 (en) | Compounds that modulate intracellular calcium | |
| RU2017120274A (ru) | Гетероарильные соединения в качестве ингибиторов irak и их применения | |
| JPWO2022007979A5 (OSRAM) | ||
| JP2013536259A5 (OSRAM) | ||
| JP2019533714A5 (OSRAM) | ||
| CN116113633A (zh) | 一种作为可透脑的btk或her2抑制剂的化合物及其制备方法与用途 | |
| JP2018537480A5 (OSRAM) | ||
| JPWO2020025517A5 (OSRAM) | ||
| JP2013530239A5 (OSRAM) | ||
| JPWO2021185256A5 (OSRAM) | ||
| JPWO2021071802A5 (OSRAM) | ||
| JPWO2021092246A5 (OSRAM) | ||
| JPWO2019213470A5 (OSRAM) | ||
| JPWO2021207530A5 (OSRAM) |